A Feasibility Study: An Evaluation of Renal Denervation Using Externally Focused Therapeutic Ultrasound on Patients With Refractory Hypertension
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 31
- 试验地点
- 4
- 主要终点
- Safety: Incidence of Adverse Events through 52 week follow-up
研究概览
简要总结
This study is a prospective, multi-center trial wherein each included subject will receive the experimental externally focused ultrasound renal denervation therapy. It will be conducted on a maximum of fifty patients who meet the inclusion and exclusion criteria and have signed the informed consent form. Safety is the primary endpoint of this study and will be assessed by incidence and evaluation of any serious adverse effects associated with the investigational procedure through the 52-week evaluation. Clinical utility is the secondary endpoint of this study and will be evaluated by assessing pre and post therapy systolic and diastolic blood pressure.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is at least 18 years of age.
- •Subject has systolic blood pressure of 160 mmHg in average or greater.
- •Subject has refractory, stable hypertension despite being treated with at least three hypertensive drugs.
- •Subject has two functioning kidneys, defined as eGFR ≥ 45 ml/min.
- •Subject has at least one renal artery on each side which is greater than 4mm.
排除标准
- •Subject has hydronephrosis as seen on MRA or ultrasound.
- •Subject has renal stenosis greater than 50% based on baseline MRA.
- •Subject has a renal stent or other implant in the region.
- •Subject has kidney stones which are symptomatic and/or greater than 1cm or in the discretion of the investigator may interfere with treatment.
- •Subject has a history of abdominal surgery within the past six months.
- •Subject has heterogeneities in the kidney such as large cysts or tumors which in the discretion of the investigator may interfere with treatment.
- •Subject has active pyelonephritis or a history of pyelonephritis which in the discretion of the investigator may interfere with treatment.
- •Subject has a history of myocardial infarction, unstable angina pectoris, or cerebrovascular accident within the last six months.
- •Subject has hemodynamically significant valvular heart disease.
- •Subject has an implantable cardioverter defibrillator, pacemaker, neurostimulator or other device incompatible with MRI.
- •Subject has a body weight > 150 kilograms.
- •Subject has a target treatment depth > 14 cm.
- •Subject is pregnant, nursing or intends to become pregnant during the trial period.
- •Subject is currently enrolled in other potentially confounding research.
- •Subject has any condition that, at the discretion of the investigator, would preclude participation in the trial.
结局指标
主要结局
Safety: Incidence of Adverse Events through 52 week follow-up
时间窗: One Year
Safety will be assessed by incidence and evaluation of any serious adverse effects associated with the investigational procedure through the 52-week evaluation of bilateral treatment. Included in this assessment will be the proportion of subjects with any of the following outcomes: (1) death, or (2) medical morbidity, including but not limited to renal artery aneurysm, stenosis, significant deterioration of renal function, fistulae or ureteral stenosis.
次要结局
- Decrease in Blood Pressure(12 and 24 weeks post therapy)